BSI-201, the first poly ADP-ribose polymerase (PARP) inhibitor in BiPar’s DNA repair portfolio, crosses the blood-brain barrier, a unique property that enables its targeted investigation in the brain tumor setting. This study is being conducted by investigators from the New Approaches to Brain Tumor Therapy (NABTT) consortium, a National Cancer Institute-funded research group.
In addition to GBM, BiPar is currently enrolling BSI-201 in a randomized Phase II trial for triple-negative breast cancer and is initiating Phase II trials in uterine and BRCA-negative ovarian cancers.
Barry Sherman, BiPar’s executive vice president, said: “The scientific observations that BSI-201 crosses the blood-brain barrier and has a mechanistic basis to synergize with the standard treatment of glioblastoma multiforme (GBM) makes this a promising study. It is the promise of this approach that encouraged the leaders of NABTT to evaluate BSI-201 in patients with GBM.”